Evaluación económica del uso de rhGH solución inyectable de 36 UI en niños con deficiencia de hormona de crecimiento, síndrome de Turner y síndrome de Prader-Willi en México-Reference-Cited by-同舟云学术

Evaluación económica del uso de rhGH solución inyectable de 36 UI en niños con deficiencia de hormona de crecimiento, síndrome de Turner y síndrome de Prader-Willi en México

Published:2014-10-25 Issue:2 Volume:12 Page:47-52
ISSN:1695-405X
Container-title:PharmacoEconomics Spanish Research Articles
language:es
Short-container-title:PharmacoEcon Span Res Artic

Author:

Pizarro Mariel,Soto Herman,Rodríguez Mauricio,Galindo Rosa María,Muciño Emilio,Medina Bravo Patricia

Publisher

Springer Science and Business Media LLC

Subject

Health Policy,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Link

http://link.springer.com/content/pdf/10.1007/s40277-014-0038-7.pdf

Reference22 articles.

1. Centers for Disease Control and Prevention. 2000. Centers of Disease Control and Prevention. CDC Growth Charts. Disponible en: http://www.cdc.gob [Acceso el 1 de octubre de 2010].

2. Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society. J Clin Endocrinol Metab. 2000;85:3990–3.

3. Lee PA. Use of GnRH agonists in GH deficient patients: arguments for and against. The case for GnRH agonists in GH deficient patients. Pediatr Endocrinol Rev. 2008;5:744–9.

4. August GP, Julius JR, Blethen SL. Adult height in children with growth hormone deficiency who are treated with biosynthetic growth hormone: the National Cooperative Growth Study experience. Pediatrics. 1998;102:512–6.

5. Baxter L, Bryant J, Cave CB, et al. Recombinant growth hormone for children and adolescents with Turner syndrome. Cochrane Database Syst Rev. 2007;CD003887.